United States Life Science Ipo Transactions

Evommune is a biopharmaceutical company developing innovative therapies in the area of chronic inflammation, particularly in dermatological conditions. Evommune was founded in 2020 and is based in Palo Alto, California.

Andera Partners
Investor
Private Equity Firm
Paris, France
www.anderapartners.com

EQT Life Sciences
Investor
Growth Capital Firm
Amsterdam, Netherlands
eqtgroup.com/private-capital/eqt-life-sciences

Caris Life Sciences is a biosciences company focused on developing and delivering innovative molecular diagnostic, prognostic and theranostic services. As an innovative biotechnology company, Caris is actively working to fulfill the promise of precision medicine through transformative platforms to help patients with cancer and other complex diseases. Caris Life Sciences was founded in 2008 and is based in Irving, Texas.

J.H. Whitney Capital Partners
Investor
Private Equity Firm
New Canaan, Connecticut
www.whitney.com

Silver Lake
Investor
Private Equity Firm
Menlo Park, California
www.silverlake.com

Mineralys is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the company is initially developing for the treatment of patients with uncontrolled hypertension. Mineralys was founded in 2019 and is based in Radnor, Pennsylvania.

Adams Street Partners
Investor
Asset Manager
Chicago, Illinois
www.adamsstreetpartners.com

Andera Partners
Investor
Private Equity Firm
Paris, France
www.anderapartners.com

HBM Partners
Investor
Private Equity Firm
Zug, Switzerland
www.hbmpartners.com

Acrivon is a proprietary, streamlined approach to develop patient selection tumor biopsy tests, called OncoSignature tests. Company’s lead molecule ACR-368 is a potent, selective inhibitor of CHK1 and CHK2 which has shown deep durable single agent activity, including complete responses, in a proportion of patients across several Phase 2 studies of platinum-resistant ovarian cancer and in squamous cell cancers, including anal cancer for which FDA has granted orphan drug designation. Acrivon was founded in 2018 and is based in Watertown, Massachusetts.

HBM Partners
Investor
Private Equity Firm
Zug, Switzerland
www.hbmpartners.com

Third Harmonic Bio is a clinical stage bio technology company developing an oral KIT inhibitor therapy for allergic autoimmune disorders. Third Harmonic Bio was founded in 2019 and is based in San Francisco, California.

General Atlantic
Investor
Growth Capital Firm
New York, New York
www.generalatlantic.com

Xilio Therapeutics is a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Xilio Therapeutics was founded in 2016 and is based in Waltham, Massachusetts.

Eight Roads
Investor
Private Equity Firm
London, United Kingdom
www.eightroads.com

Pyxis Oncology specializes in developing a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis Oncology was founded in 2018 and is based in Boston, Massachusetts.

HBM Partners
Investor
Private Equity Firm
Zug, Switzerland
www.hbmpartners.com

Whitehawk Therapeutics is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Whitehawk Therapeutics was founded in 2007 and is headquartered in Morristown, New Jersey.

Hermed Capital Co. Ltd.
Investor
Growth Capital Firm
Shanghai, China
www.hermedcapital.com

Eliem Therapeutics is a biotech company developing drugs for neurological disorders. Eliem Therapeutics is based in Redmond, Washington.

ICG
Investor
Mezzanine Finance Firm
London, United Kingdom
www.icgam.com

Icosavax is a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Icosavax was founded in 2017 and is based in Seattle, Washington.

Adams Street Partners
Investor
Asset Manager
Chicago, Illinois
www.adamsstreetpartners.com

Immuneering is a trusted advisor to pharmaceutical companies, pioneering new analyses to identify biological insights that improve patients’ lives. Immuneering’s team of experts provides advanced data analysis services using state-of-the-art technologies including proprietary algorithms. The company is a rapidly growing company with seven years of experience analyzing data sets ranging from gene expression (microarray) data, to single-nucleotide polymorphism (SNP) data, to protein concentration data, to clinical metadata, to next-generation sequencing (NGS) data including RNA seq, exome sequencing, and whole-genome sequencing. Using these data sets, Immuneering captures difficult-to-find signals, generates biological hypotheses, and designs follow-up studies, contributing to the development of medicines for patients with a wide range of serious diseases. Immuneering was formed in 2008 and is based in Cambridge, Massachusetts.

Teva Pharmaceutical Industries
Company
Life Science
Tel Aviv, Israel
www.tevapharm.com

Cytek is a cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with exquisite sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights systems, reagents, cell sorter, software, and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek was founded in 1992 and is based in Fremont, California.

Eight Roads
Investor
Private Equity Firm
London, United Kingdom
www.eightroads.com

Caribou Biosciences is an operator of a medical technology company intended to analyze cell and genome engineering. The company specializes in cellular engineering and analysis based on the CRISPR-Cas9 technology platform which paired with a guide RNA, cuts double-stranded DNA and allows for specific changes to DNA, enabling development of therapeutics for agricultural biotechnology, industrial biotechnology and basic and applied biological research. Caribou Biosciences was founded in 2011 and is based in Berkeley, California.

Eight Roads
Investor
Private Equity Firm
London, United Kingdom
www.eightroads.com

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago BioSciences was formed in 2012 and is based in South San Francisco, California.

Frazier Healthcare Partners
Investor
Growth Capital Firm
Seattle, Washington
www.frazierhealthcare.com

Rapid Micro Biosystems is a life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Rapid Micro Biosystems was founded in 2006 and is based in Lowell, Massachusetts.

TPG
Investor
Private Equity Firm
Fort Worth, Texas
www.tpg.com

Teknova is a manufacturer and sells cell culture media and buffers into the research and bioproduction markets. Teknova is based in Hollister, California.

Telegraph Hill Partners
Investor
Venture Capital Firm
San Francisco, California
www.thpartners.net